Home
/
PALVELLA THERAPEUTICS, INC.
/
Financials
/
Quarterly
PALVELLA THERAPEUTICS, INC. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that PALVELLA THERAPEUTICS, INC. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2024
Sep 30, 2024
$0
Nov 13, 2024
Q2
2024
Jun 30, 2024
$0
Aug 14, 2024
Q1
2024
Mar 31, 2024
$53.0K
May 15, 2024
Q3
2024
Sep 30, 2023
$19.52M
Nov 13, 2024
Q2
2024
Jun 30, 2023
$20.06M
Aug 14, 2024
Q1
2024
Mar 31, 2023
$1.94M
May 15, 2024
Q3
2023
Sep 30, 2022
$5.37M
Nov 14, 2023
Q2
2023
Jun 30, 2022
$3.70M
Aug 10, 2023
Q1
2023
Mar 31, 2022
$10.99M
May 11, 2023
Q3
2022
Sep 30, 2021
$4.06M
Nov 4, 2022
Q2
2022
Jun 30, 2021
$3.29M
Aug 4, 2022
Q1
2022
Mar 31, 2021
$15.63M
May 11, 2022
Q3
2021
Sep 30, 2020
$2.94M
Nov 2, 2021
Q2
2021
Jun 30, 2020
$11.25M
Aug 5, 2021
Q1
2021
Mar 31, 2020
$13.26M
May 17, 2021
Q3
2020
Sep 30, 2019
$15.13M
Nov 4, 2020
Q2
2020
Jun 30, 2019
$5.33M
Aug 10, 2020
Q1
2020
Mar 31, 2019
$8.55M
May 11, 2020
Q3
2019
Sep 30, 2018
$8.35M
Nov 12, 2019
Q2
2019
Jun 30, 2018
$11.69M
Aug 9, 2019
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2019
Sep 30, 2019
$14.50M
Nov 12, 2019
Q2
2019
Jun 30, 2019
$4.93M
Aug 9, 2019
Q1
2019
Mar 31, 2019
$7.53M
May 10, 2019
Q3
2019
Sep 30, 2018
$7.87M
Nov 12, 2019
Q2
2019
Jun 30, 2018
$11.22M
Aug 9, 2019
Q1
2019
Mar 31, 2018
$3.44M
May 10, 2019
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($11.35M)
Nov 12, 2025
Q2
2025
Jun 30, 2025
($9.47M)
Aug 14, 2025
Q3
2025
Jun 30, 2025
($9.47M)
Nov 12, 2025
Q1
2025
Mar 31, 2025
($8.19M)
May 15, 2025
Q3
2025
Mar 31, 2025
($8.19M)
Nov 12, 2025
Q2
2025
Mar 31, 2025
($8.19M)
Aug 14, 2025
Q3
2025
Dec 31, 2024
($17.40M)
Nov 12, 2025
Q1
2025
Dec 31, 2024
($17.40M)
May 15, 2025
Q2
2025
Dec 31, 2024
($17.40M)
Aug 14, 2025
Q3
2025
Sep 30, 2024
($6.78M)
Nov 12, 2025
Q3
2025
Jun 30, 2024
($4.17M)
Nov 12, 2025
Q2
2025
Jun 30, 2024
($4.17M)
Aug 14, 2025
Q1
2025
Mar 31, 2024
($2.54M)
May 15, 2025
Q3
2025
Mar 31, 2024
($2.54M)
Nov 12, 2025
Q2
2025
Mar 31, 2024
($2.54M)
Aug 14, 2025
Q3
2024
Sep 30, 2023
($10.75M)
Nov 13, 2024
Q2
2024
Jun 30, 2023
$3.98M
Aug 14, 2024
Q1
2024
Mar 31, 2023
($13.18M)
May 15, 2024
Q3
2023
Sep 30, 2022
($9.74M)
Nov 14, 2023
Q2
2023
Jun 30, 2022
($10.34M)
Aug 10, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($10.18M)
Nov 12, 2025
Q2
2025
Jun 30, 2025
($9.25M)
Aug 14, 2025
Q1
2025
Mar 31, 2025
($7.87M)
May 15, 2025
Q3
2025
Sep 30, 2024
($5.06M)
Nov 12, 2025
Q2
2025
Jun 30, 2024
($2.91M)
Aug 14, 2025
Q1
2025
Mar 31, 2024
($1.76M)
May 15, 2025
Q3
2024
Sep 30, 2023
($11.81M)
Nov 13, 2024
Q2
2024
Jun 30, 2023
$2.06M
Aug 14, 2024
Q1
2024
Mar 31, 2023
($15.51M)
May 15, 2024
Q3
2023
Sep 30, 2022
($12.17M)
Nov 14, 2023
Q2
2023
Jun 30, 2022
($12.33M)
Aug 10, 2023
Q1
2023
Mar 31, 2022
($7.46M)
May 11, 2023
Q3
2022
Sep 30, 2021
($19.01M)
Nov 4, 2022
Q2
2022
Jun 30, 2021
($16.76M)
Aug 4, 2022
Q1
2022
Mar 31, 2021
($5.06M)
May 11, 2022
Q3
2021
Sep 30, 2020
($13.00M)
Nov 2, 2021
Q2
2021
Jun 30, 2020
($4.66M)
Aug 5, 2021
Q1
2021
Mar 31, 2020
($3.86M)
May 17, 2021
Q3
2020
Sep 30, 2019
($2.91M)
Nov 4, 2020
Q2
2020
Jun 30, 2019
($12.23M)
Aug 10, 2020